Impact of preoperative inflammatory and nutritional markers on the prognosis of patients with peritoneal metastasis of colorectal cancer

doi:10.4251/wjgo.v16.i9.3865

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (70)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-4)

Tables (1-3)

Sum=57

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=2

Sep 15, 2024 (publication date) through Sep 10, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Sep 15, 2024; 16(9): 3865-3874
Published online Sep 15, 2024. doi: 10.4251/wjgo.v16.i9.3865

Table 1 Characteristics of patients with peritoneal metastases of colorectal cancer

Variables	Number of patients
Age (years), n (%)
≥ 60	64 (48.2)
< 60	69 (51.8)
Sex, n (%)
Male	89 (66.9)
Female	66 (33.1)
T category, n (%)
T0-3	56 (42.2)
T4	77 (57.8)
N category, n (%)
N0-1	72 (55.6)
N2	59 (44.4)
Location of tumor, n (%)
Right side of the colon	56 (42.2)
Left side of the colon	77 (57.8)
BMI (kg/m²), n (%)
≥ 18.5	24 (18.1)
< 18.5	109 (81.9)
PCI, n (%)
≥ 20	51 (38.3)
< 20	82 (61.6)
Histology, n (%)
Adenocarcinoma	105 (78.9)
Mucinous adenocarcinoma and signet-ring cell carcinoma	28 (21.1)
CRS, n (%)
CC 0/1	57 (42.8)
CC 2	76 (57.2)
HIPEC, n (%)
Yes	35 (26.4)
No	98 (73.6)
NLR, n (%)
≥ 3.1	54 (40.6)
< 3.1	79 (59.4)
Hb, n (%)
Normal	94 (70.6)
Low	39 (29.4)
Albumin (g/L), n (%)
≥ 35	99 (74.5)
< 35	34 (25.5)

BMI: Body mass index; CRS: Cytoreductive surgery; HIPEC: Hyperthermic intraperitoneal chemotherapy; PCI: Peritoneal cancer index; NLR: Neutrophil-to-lymphocyte ratio; Hb: Hemoglobin.

Table 2 Summary of demographics for patients treated with cytoreductive surgery according to the neutrophil-to-lymphocyte ratio/hemoglobin status

variables	NLR ≥ 3.1, n = 54	NLR < 3.1, n = 79	P value	Hb (normal), n = 94	Hb (low), n = 39	P value
Age (years), n (%)			0.531			0.017
≥ 60	31 (57.4)	41 (51.8)		39 (41.5)	25 (64.1)
< 60	23 (42.6)	38 (48.2)		55 (58.5)	14 (35.9)
Sex, n (%)			0.423			0.097
Male	34 (62.9)	55 (69.6)		67 (71.2)	22 (56.4)
Female	20 (37.1)	24 (30.4)		27 (28.7)	17 (43.6)
T category, n (%)			0.177			0.187
T0-3	24 (44.4)	26 (32.9)		43 (45.7)	13 (33.3)
T4	30 (55.6)	53 (67.1)		51 (54.2)	26 (66.7)
N category, n (%)			0.710			0.029
N0-1	29 (53.7)	45 (56.9)		58 (61.7)	16 (41.1)
N2	25 (46.3)	34 (43.1)		36 (38.2)	23 (58.9)
CRS, n (%)			0.014			0.001
CC 0/1	30 (55.6)	27 (34.1)		49 (52.1)	8 (20.5)
CC 2	24 (44.4)	52 (65.9)		45 (47.9)	31 (79.5)
HIPEC, n (%)			0.473			0.065
Yes	16 (29.6)	19 (24.1)		29 (30.8)	6 (15.3)
No	38 (70.4)	60 (75.9)		65 (69.2)	33 (84.7)
Albumin (g/L), n (%)			0.019			< 0.001
≥ 35	46 (85.1)	53 (67.1)		78 (82.9)	21 (53.9)
< 35	8 (14.8)	26 (32.9)		16 (17.1)	18 (46.1)
BMI (kg/m²), n (%)			0.907			0.985
≥ 18.5	44 (81.5)	65 (82.3)		77 (82.0)	32 (82.1)
< 18.5	10 (18.5)	14 (17.7)		17 (18.0)	7 (17.9)
Location of tumor, n (%)			0.320			0.319
Right side of the colon	16 (29.6)	30 (37.9)		35 (37.2)	11 (28.2)
Left side of the colon	38 (70.4)	49 (62.1)		59 (62.8)	28 (71.8)
PCI, n (%)			0.535			0.708
≥ 20	19 (35.1)	32 (40.5)		37 (39.3)	14 (35.8)
< 20	35 (64.8)	47 (59.5)		57 (60.7)	25 (64.2)
Histology, n (%)			0.305			0.572
Adenocarcinoma	45 (83.3)	60 (75.9)		73 (77.6)	32 (82.1)
Mucinous adenocarcinoma and signet-ring cell carcinoma	9 (16.6)	19 (24.1)		21 (22.4)	7 (17.9)

BMI: Body mass index; CRS: Cytoreductive surgery; HIPEC: Hyperthermic intraperitoneal chemotherapy; PCI: Peritoneal cancer index; NLR: Neutrophil-to-lymphocyte ratio; Hb: Hemoglobin.

Table 3 Cox univariate and multivariate analyses of the 133 patients with peritoneal metastases of colorectal cancer

Variables	Univariate analysis		Multivariate analysis
Variables	HR (95%CI)	P value	HR (95%CI)	P value
Sex (female)	0.89 (0.56-1.41)	0.621
Age (≤ 60)	0.55 (0.35-0.84)	0.006	0.63 (0.39-1.01)	0.050
CEA (≥ 5.0 ng/mL)	0.88 (0.73-1.75)	0.570
CA199 (≥ 37.0 U/mL)	1.71 (1.11-2.61)	0.014	1. 19 (0.74-1.91)	0.450
CA125 (≥ 35.0 U/mL)	1.07 (0.69-1.65)	0.769
BMI (< 18.5 kg/m²)	1.22 (0.88-1.62)	0.356
Location (right side)	0.94 (0.64-1.38)	0.756
NLR (≥ 3.1)	2.02 (1.28-3.19)	0.002	1.81 (1.13-2.89)	0.010
Hb (normal)	0.47 (0.31-0.72)	< 0.001	0.65 (0.39-1.07)	0.080
Albumin (< 35 g/L)	2.11 (1.37-3.51)	< 0.001	1.25 (0.72-2.17)	0.420
Category (T4)	1.04 (0.68-1.59)	0.854
Category (N2)	1.02 (0.79-1.21)	0.857
Histology (mucinous adenocarcinoma and signet-ring cell carcinoma)	1.46 (0.94-2.27)	0.090
PCI (≥ 20)	1.91 (1.24-2.93)	0.003	1.92 (1.21-3.07)	0.006

HR: Hazard ratio; CI: Confidence interval; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen 199; CA125: Carbohydrate antigen 125; BMI: Body mass index; NLR: Neutrophil-to-lymphocyte ratio; Hb: Hemoglobin; PCI: Peritoneal cancer index.

Citation: Wu ZJ, Lan B, Luo J, Ameti A, Wang H, Hu QY. Impact of preoperative inflammatory and nutritional markers on the prognosis of patients with peritoneal metastasis of colorectal cancer. World J Gastrointest Oncol 2024; 16(9): 3865-3874
URL: https://www.wjgnet.com/1948-5204/full/v16/i9/3865.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i9.3865